A Comprehensive Clinical Monograph on Tenofovir Alafenamide (DB09299)

Executive Summary

Tenofovir alafenamide (TAF) is a novel, second-generation prodrug of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir, representing a significant advancement in the management of Human Immunodeficiency Virus 1 (HIV-1) and chronic Hepatitis B Virus (HBV) infections. Developed by Gilead Sciences utilizing advanced "ProTide" phosphonamidate chemistry, TAF was engineered to overcome the primary long-term safety limitations of its predecessor, tenofovir disoproxil fumarate (TDF), namely nephrotoxicity and reductions in bone mineral density. The core innovation of TAF lies in its unique pharmacokinetic profile; it exhibits high stability in plasma, allowing for efficient delivery to and activation within target cells such as hepatocytes and lymphocytes. This targeted mechanism results in intracellular concentrations of the active metabolite, tenofovir diphosphate, that are up to 20-fold higher than those achieved with TDF, while simultaneously reducing systemic plasma tenofovir levels by over 90%.

This optimized delivery allows for a more than ten-fold reduction in the required oral dose (typically 25 mg for TAF vs. 300 mg for TDF), achieving non-inferior antiviral efficacy against both HIV-1 and HBV. Clinically, this translates into a markedly improved safety profile. Extensive clinical data, including long-term 8-year studies, consistently demonstrate that TAF is associated with significantly smaller decreases in estimated glomerular filtration rate (eGFR), less proteinuria, and a lower incidence of clinically significant renal events, including the absence of reported proximal renal tubulopathy in major trials. Similarly, TAF has a more favorable impact on bone health, causing significantly less reduction in bone mineral density at the hip and spine, with evidence of bone mass recovery in patients who switch from TDF.

TAF is available as a standalone agent for HBV (Vemlidy®) and as a component of multiple leading fixed-dose combination and single-tablet regimens for HIV-1 treatment and prevention (e.g., Descovy®, Genvoya®, Odefsey®, Biktarvy®). However, the clinical benefits of TAF are accompanied by a distinct metabolic trade-off. Compared to the lipid-lowering effect of TDF, TAF is associated with increases in total cholesterol, LDL-cholesterol, and triglycerides, as well as greater weight gain in some patient populations. This necessitates careful patient selection and lipid monitoring. The choice between TAF and TDF is therefore a nuanced clinical decision, balancing the clear renal and bone advantages of TAF against its metabolic effects, patient comorbidities, and, in some contexts, the cost-effectiveness of generic TDF.

Introduction: The Evolution of Tenofovir Therapy

Development Rationale for Tenofovir Alafenamide (TAF)

The nucleotide analogue tenofovir has long been a cornerstone of antiviral therapy, forming the backbone of recommended treatment regimens for both HIV-1 and chronic HBV infections worldwide.[1] Its initial oral formulation, tenofovir disoproxil fumarate (TDF), demonstrated potent and durable viral suppression and was generally well-tolerated.[2] However, the advent of lifelong antiretroviral therapy for HIV and long-term treatment for HBV brought the cumulative toxicities of medications into sharp focus. Over years of clinical use, a clear safety signal emerged linking long-term TDF administration with an increased risk of nephrotoxicity, including renal tubular dysfunction (Fanconi syndrome), and significant reductions in bone mineral density (BMD).[1] These adverse effects were mechanistically linked to the high systemic plasma concentrations of tenofovir required to achieve therapeutic intracellular levels of the active drug.[1] This created a pressing unmet medical need for a new formulation of tenofovir that could preserve the high antiviral efficacy of TDF while mitigating its off-target exposure to the kidneys and bones.

The "ProTide" Technology and its Clinical Promise

Tenofovir alafenamide (TAF) was developed by Gilead Sciences as a direct response to this clinical challenge. TAF is a novel phosphonamidate prodrug engineered using the "ProTide" (prodrug nucleotide) technology.[8] This sophisticated chemical strategy involves masking the highly polar and negatively charged phosphonic acid group of tenofovir with two specific lipophilic moieties: a phenoxy group and an L-alanine isopropyl ester.[9] This structural modification fundamentally alters the drug's disposition in the body.

The central premise behind TAF's design was to create a molecule with enhanced plasma stability and improved passive diffusion into target cells (lymphocytes and hepatocytes).[2] Once inside the target cell, TAF is efficiently cleaved by the intracellular enzyme Cathepsin A, releasing tenofovir, which is then phosphorylated to the active antiviral agent, tenofovir diphosphate (TFV-DP).[9] This targeted intracellular activation mechanism was hypothesized to allow for much higher concentrations of TFV-DP where it is needed—within the virus-infected cells—while dramatically lowering the concentration of tenofovir circulating in the plasma. This pharmacokinetic separation promised to uncouple efficacy from off-target toxicity, allowing for a significantly lower oral dose while improving the long-term safety profile. This approach represents a significant evolution in antiretroviral drug design, shifting the focus from maximizing systemic drug levels to optimizing targeted intracellular delivery, a critical consideration for managing chronic diseases that require lifelong therapy.

Chemical Profile and Physicochemical Properties

A precise understanding of the chemical and physical characteristics of tenofovir alafenamide is fundamental to its pharmacology and formulation.

Nomenclature and Identification

Tenofovir alafenamide is a small molecule drug identified by a consistent set of chemical names and database codes, ensuring its unambiguous identification in scientific literature and regulatory filings.

• Chemical Name: (S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate [9]
• IUPAC Name: Isopropyl (2S)-2-methyl-phenoxy-phosphoryl]amino]propanoate [8]
• Common Synonyms: TAF, GS-7340 [8]
• Key Database Identifiers:
• DrugBank ID: DB09299 [8]
• CAS Number: 379270-37-8 [8]
• PubChem CID: 9574768 [8]
• UNII: EL9943AG5J [8]

Structural Characteristics and Formulation (TAF vs. TAF Fumarate)

The molecular structure of TAF is key to its function as a targeted prodrug.

• Molecular Formula: C21​H29​N6​O5​P [8]
• Molar Mass: 476.474 g·mol⁻¹ [8]
• Structural Representation:
• SMILES: C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3 [8]
• InChIKey: LDEKQSIMHVQZJK-CAQYMETFSA-N [8]

In its pharmaceutical preparations, the active moiety TAF is formulated as a salt to enhance stability and handling properties. It is most commonly administered as tenofovir alafenamide fumarate.[8] The prescribing information for Vemlidy®, for instance, clarifies that one 25 mg tablet of tenofovir alafenamide is equivalent to 28 mg of tenofovir alafenamide fumarate.[16] Some sources also refer to this as a hemifumarate or a 2:1 salt of TAF to fumaric acid.[17]

Solubility, Stability, and Other Physical Attributes

The physical properties of TAF influence its absorption, distribution, and formulation requirements. A summary of these properties is provided in Table 1.

---

Table 1: Chemical and Physical Identifiers of Tenofovir Alafenamide

Property	Value	Source(s)
DrugBank ID	DB09299	8
CAS Number	379270-37-8	8
Molecular Formula	C21​H29​N6​O5​P	8
Molar Mass	476.474 g·mol⁻¹	8
Appearance	White to Off-White/Beige Solid Powder	14
Melting Point	104-107 °C; >119 °C (decomposition)	10
Boiling Point	640.4 ± 65.0 °C (Predicted)	10
Solubility (Water)	4.86 mg/mL at 20 °C; noted as slightly soluble	10
Solubility (DMSO)	55 - 95 mg/mL	13
Solubility (Ethanol)	88 - 95 mg/mL	13
Dissociation Constant (pKa)	3.96	10
LogP	1.6	10
Stability	Hygroscopic	19

---

Clinical Pharmacology: A Targeted Approach

The entire clinical profile of TAF—its efficacy, safety, and drug interaction potential—is a direct consequence of its unique pharmacology, which was intentionally designed to optimize the therapeutic index of tenofovir.

A. Mechanism of Action: Intracellular Activation and Viral Inhibition

Tenofovir alafenamide functions as a highly targeted delivery system for the active antiviral agent, tenofovir.[8] Its mechanism can be broken down into a multi-step intracellular process:

1. Cellular Uptake: Following oral administration and absorption, TAF circulates in the plasma. Its lipophilic nature facilitates entry into target cells—primarily hepatocytes for HBV and peripheral blood mononuclear cells (PBMCs) like CD4+ T-lymphocytes for HIV—through a combination of passive diffusion and active transport via the hepatic uptake transporters OATP1B1 and OATP1B3.[9]
2. Intracellular Hydrolysis: TAF is engineered to be highly stable in plasma but is rapidly metabolized once inside the target cell. The intracellular enzyme Cathepsin A (or carboxylesterase 1 in hepatocytes) efficiently hydrolyzes the phosphonamidate bond, releasing the parent molecule, tenofovir (TFV), directly into the cytoplasm.[9] This intracellular conversion is the critical step that concentrates the drug where it is needed.
3. Activation via Phosphorylation: The liberated tenofovir is then phosphorylated by cellular kinases through two successive steps to form its pharmacologically active metabolite, tenofovir diphosphate (TFV-DP).[9]
4. Viral Inhibition: TFV-DP is a structural analog of the natural substrate deoxyadenosine 5'-triphosphate (dATP). It acts as a competitive inhibitor of viral reverse transcriptase (in both HIV and HBV) and also functions as a chain terminator.[9] By incorporating into the elongating strand of viral DNA, TFV-DP's acyclic structure prevents the formation of the next phosphodiester bond, thereby halting DNA synthesis and preventing viral replication.[9]

B. Pharmacokinetic Profile (ADME): Optimizing Drug Delivery

The pharmacokinetic properties of TAF are fundamentally different from those of TDF and are the key to its improved safety profile.

• Absorption: The prodrug design significantly enhances oral bioavailability.[11] TAF is rapidly absorbed, with peak plasma concentrations occurring approximately 0.5-2 hours after administration.[8] Administration with food, particularly a high-fat meal, increases the area under the curve (AUC) by approximately 65%, which is why several TAF-containing regimens are recommended to be taken with food.[11]
• Distribution: TAF is approximately 80% bound to human plasma proteins and demonstrates high stability in the plasma, minimizing premature conversion to tenofovir in the systemic circulation.[8] This stability allows the intact prodrug to reach and accumulate in target lymphoid tissues and hepatocytes more effectively than TDF.[8]
• Metabolism: As noted, the primary metabolic pathway is intracellular hydrolysis to tenofovir. TAF itself is a substrate of the efflux transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), a characteristic that underlies its most clinically significant drug-drug interactions.[16]
• Excretion: Elimination occurs through multiple pathways. After an oral dose, 31.7% is excreted in feces and less than 1% in urine as unchanged TAF.[8] The active metabolite, tenofovir, is primarily cleared by the kidneys via glomerular filtration and active tubular secretion.[16] The plasma half-life of TAF itself is very short, at approximately 0.51 hours, reflecting its rapid clearance from plasma and uptake into cells.[8]

C. Pharmacodynamics: Potency Against HIV-1 and HBV

The pharmacodynamic effects of TAF are a direct result of its efficient intracellular delivery. The most critical pharmacodynamic distinction between TAF and TDF is the resulting concentration gradient between plasma and target cells. Clinical studies have demonstrated that TAF achieves:

• 91% lower plasma concentrations of tenofovir compared to TDF.[1]
• Approximately 20-fold higher intracellular concentrations of the active metabolite, TFV-DP, in PBMCs.[1]

This remarkable efficiency allows for a much lower oral dose of TAF (e.g., 10 mg or 25 mg) to exert antiviral activity that is non-inferior, and in some cases superior, to a 300 mg dose of TDF.[1] In vitro studies confirm potent anti-HIV activity with an EC50 value of approximately 5 nM.[12] TAF is a potent inhibitor of HBV replication and is active against a wide range of HIV-1 subtypes.[11]

Global Regulatory and Approval History

The regulatory history of tenofovir alafenamide illustrates a highly successful and deliberate pharmaceutical strategy by Gilead Sciences. The approvals followed a phased global rollout designed to first establish TAF within a premium single-tablet regimen, then unbundle it as a foundational backbone to replace TDF across various combinations, and finally expand its use into new therapeutic areas and patient populations. This strategic sequence maximized its clinical impact and commercial potential.

A. U.S. Food and Drug Administration (FDA) Milestones

The FDA approvals for TAF-based regimens occurred in rapid succession, reflecting the strength of the clinical data and the strategic importance of the molecule.

• Genvoya® (elvitegravir/cobicistat/emtricitabine/TAF): The first TAF-based regimen received FDA approval on November 5, 2015, for the treatment of HIV-1.[8]
• Odefsey® (rilpivirine/emtricitabine/TAF): Approved in March 2016 for HIV-1 treatment.[8]
• Descovy® (emtricitabine/TAF): Approved on April 4, 2016, as a two-drug backbone for HIV-1 treatment regimens.[8] Its indication was significantly expanded on October 3, 2019, to include HIV-1 pre-exposure prophylaxis (PrEP).[8]
• Vemlidy® (TAF): The standalone formulation was approved on November 10, 2016, for the treatment of chronic HBV infection in adults.[8] This indication has since been expanded to pediatric populations, first to adolescents aged 12 and older in November 2022, and then to children aged 6 and older (weighing ≥25 kg) on March 28, 2024.[26]
• Biktarvy® (bictegravir/emtricitabine/TAF): Approved in February 2018 as a complete single-tablet regimen for HIV-1.[8]
• Symtuza® (darunavir/cobicistat/emtricitabine/TAF): Approved in July 2018, becoming the first protease inhibitor-based single-tablet regimen containing TAF.[8]

B. European Medicines Agency (EMA) Authorizations

The EMA review and approval process largely mirrored that of the FDA, establishing TAF as a standard of care across Europe.

• Genvoya®: Received marketing authorization in November 2015.[8]
• Descovy®: Granted marketing authorization valid throughout the European Union on April 21, 2016.[30]
• Odefsey®: Approved in June 2016.[8]
• Vemlidy®: Received marketing authorization on January 9, 2017.[32]
• Symtuza®: Approved in September 2017.[8]
• Biktarvy®: Authorized for use in the EU for the treatment of HIV-1 infection.[33]

A timeline summarizing these key regulatory milestones is provided in Table 2.

---

Table 2: Timeline of Key FDA and EMA Approvals for TAF-Based Regimens

Date	Regulatory Agency	Brand Name (Formulation)	Approved Indication
Nov 2015	FDA & EMA	Genvoya® (E/C/F/TAF)	HIV-1 Treatment
Mar 2016	FDA	Odefsey® (R/F/TAF)	HIV-1 Treatment
Apr 2016	FDA & EMA	Descovy® (F/TAF)	HIV-1 Treatment (Backbone)
Jun 2016	EMA	Odefsey® (R/F/TAF)	HIV-1 Treatment
Nov 2016	FDA	Vemlidy® (TAF)	Chronic HBV Treatment (Adults)
Jan 2017	EMA	Vemlidy® (TAF)	Chronic HBV Treatment
Sep 2017	EMA	Symtuza® (D/C/F/TAF)	HIV-1 Treatment
Feb 2018	FDA	Biktarvy® (B/F/TAF)	HIV-1 Treatment
Jul 2018	FDA	Symtuza® (D/C/F/TAF)	HIV-1 Treatment
Oct 2019	FDA	Descovy® (F/TAF)	HIV-1 Pre-Exposure Prophylaxis (PrEP)
Nov 2022	FDA	Vemlidy® (TAF)	Chronic HBV Treatment (Pediatrics ≥12 yrs)
Mar 2024	FDA	Vemlidy® (TAF)	Chronic HBV Treatment (Pediatrics ≥6 yrs)

---

C. Generic Status and Market Exclusivity Insights

While the FDA has approved tenofovir alafenamide for manufacture as a generic medication, it is not yet commercially available in the United States as of mid-2024.[8] In Europe, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a generic version of emtricitabine/tenofovir alafenamide (Descovy) in May 2025, having confirmed its bioequivalence to the branded product.[30] The initial marketing of TAF was protected by New Chemical Entity (NCE) exclusivity. The manufacturer sought to apply an "umbrella exclusivity" policy, whereby the five-year exclusivity granted to the first approved TAF product (Genvoya) would extend to subsequent products containing the same active moiety, thereby protecting the entire TAF franchise.[24]

Therapeutic Landscape: TAF-Based Regimens

Tenofovir alafenamide is not a single product but the core component of a diverse portfolio of antiviral therapies. Each formulation is tailored for specific clinical scenarios in the management of HBV and HIV-1. A summary of these regimens is provided in Table 3.

---

Table 3: Summary of Approved TAF-Containing Formulations and Indications

Brand Name	Composition (Active Ingredients & Strengths)	Primary Indication(s)	Key Administration Notes
Vemlidy®	Tenofovir Alafenamide (TAF) 25 mg	Chronic Hepatitis B (HBV) treatment in adults and children (≥6 yrs, ≥25 kg) with compensated liver disease.	One tablet once daily with food.
Descovy®	Emtricitabine (FTC) 200 mg / TAF 25 mg	HIV-1 Treatment: Backbone therapy in combination with other antiretrovirals (in patients ≥25 kg). HIV-1 PrEP: To reduce risk of sexually acquired HIV-1 (in individuals ≥35 kg), excluding risk from receptive vaginal sex.	One tablet once daily with or without food.
Genvoya®	Elvitegravir 150 mg / Cobicistat 150 mg / FTC 200 mg / TAF 10 mg	HIV-1 Treatment (complete single-tablet regimen) in treatment-naïve or virologically suppressed patients (≥25 kg).	One tablet once daily with food.
Odefsey®	Rilpivirine 25 mg / FTC 200 mg / TAF 25 mg	HIV-1 Treatment (complete single-tablet regimen) in patients with baseline viral load ≤100,000 copies/mL or as a switch for suppressed patients.	One tablet once daily with a meal.
Biktarvy®	Bictegravir 50 mg / FTC 200 mg / TAF 25 mg	HIV-1 Treatment (complete single-tablet regimen) in treatment-naïve or virologically suppressed patients.	One tablet once daily with or without food.
Symtuza®	Darunavir 800 mg / Cobicistat 150 mg / FTC 200 mg / TAF 10 mg	HIV-1 Treatment (complete single-tablet regimen), particularly for patients requiring a high-resistance-barrier protease inhibitor.	One tablet once daily with food.

---

A. Vemlidy® (TAF): Monotherapy for Chronic Hepatitis B

Vemlidy is the standalone formulation of TAF, specifically indicated for the treatment of chronic HBV infection in patients with compensated liver disease.[8] Administered as a single 25 mg tablet once daily with food, its approval was based on data from two pivotal Phase 3 trials (Study 108 in HBeAg-negative patients and Study 110 in HBeAg-positive patients). These studies demonstrated that Vemlidy was non-inferior to TDF in achieving viral suppression at 48 and 96 weeks, but with statistically significant improvements in markers of renal and bone safety.[21] Its indication has been progressively expanded to include pediatric patients as young as six years old.[27]

B. Descovy® (Emtricitabine/TAF): A Foundational Backbone for HIV-1 Treatment and PrEP

Descovy co-formulates TAF with emtricitabine (FTC), another NRTI, to create a two-drug backbone that is combined with a third agent (such as an integrase inhibitor or protease inhibitor) to form a complete HIV-1 treatment regimen.[25] It serves as the direct successor to the widely used F/TDF combination (Truvada®). Its approval for PrEP in 2019 marked a significant expansion of its use, offering an alternative to Truvada with a more favorable renal and bone safety profile.[25] However, its PrEP indication is notably limited to men and transgender women who have sex with men, as its effectiveness for preventing HIV acquisition through receptive vaginal sex has not been studied.[37]

C. Single-Tablet Regimens for HIV-1 Treatment

The integration of TAF into single-tablet regimens (STRs) has been a key part of its clinical success, offering patients convenient, potent, and safer long-term treatment options.

• Genvoya® was the first TAF-based STR, combining the F/TAF backbone with the integrase inhibitor elvitegravir, boosted by cobicistat.[8] The presence of the pharmacokinetic booster cobicistat necessitates a lower dose of TAF (10 mg).[41] It is taken once daily with food.[22]
• Odefsey® combines the F/TAF backbone with the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine.[43] It is indicated for patients with a baseline viral load of 100,000 copies/mL or less and must be taken with a meal to ensure adequate absorption of rilpivirine.[45]
• Biktarvy® has become one of the most widely prescribed antiretroviral regimens, combining the F/TAF backbone with the potent, unboosted second-generation integrase inhibitor bictegravir.[29] Its high efficacy, high barrier to resistance, minimal drug interactions, and convenient dosing (once daily with or without food) have made it a preferred first-line option.[33]
• Symtuza® is the first and only STR based on the potent and high-resistance-barrier protease inhibitor darunavir.[8] Like Genvoya, it contains cobicistat as a booster, requiring the 10 mg dose of TAF, and must be taken with food.[11]

Comprehensive Safety and Tolerability Analysis

While TAF was developed specifically for an improved safety profile, it is associated with a distinct set of risks, warnings, and adverse effects that require careful clinical management.

A. Boxed Warnings: Critical Risks and Clinical Management

All TAF-containing products carry boxed warnings for potentially severe adverse events.

• Post-Treatment Severe Acute Exacerbation of Hepatitis B: This is the most critical warning and applies to all TAF formulations. Discontinuation of TAF in patients with HBV infection (either as monotherapy or in those co-infected with HIV-1) can lead to a severe, acute flare-up of hepatitis. Therefore, all patients should be tested for HBV before initiating a TAF-containing regimen. Patients with HBV who discontinue the drug must be monitored closely with both clinical and laboratory follow-up of hepatic function for at least several months. If appropriate, resumption of anti-hepatitis B therapy may be warranted.[16]
• Risk of Drug Resistance with PrEP Use (Descovy only): This warning is specific to the use of Descovy for HIV-1 PrEP. Descovy is contraindicated for PrEP in individuals with an unknown or positive HIV-1 status. It is imperative to confirm a negative HIV-1 test immediately before starting and at least every three months during use. Initiating PrEP during an undiagnosed acute HIV-1 infection can lead to the selection of drug-resistant viral variants, compromising future treatment options.[37]
• Lactic Acidosis and Severe Hepatomegaly with Steatosis: This is a class warning for all NRTIs. Although rare, this is a life-threatening condition. Treatment with TAF should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity.[16]

B. Adverse Reaction Profile: From Common to Clinically Significant

The overall adverse reaction profile of TAF is generally favorable.

• Common Adverse Reactions: In clinical trials for HBV and HIV treatment, the most frequently reported adverse events (incidence ≥5%) include headache (9-12%), abdominal pain, cough, fatigue, nausea, back pain, and arthralgia.[47] In the DISCOVER trial for PrEP, the most common adverse reaction was diarrhea (5%).[37]
• Laboratory Abnormalities: Clinically significant laboratory abnormalities can include elevations in LDL-cholesterol, creatine kinase, and serum amylase, as well as the presence of glycosuria.[47]
• Serious and Postmarketing Adverse Reactions: While the risk is lower than with TDF, new onset or worsening renal impairment, including cases of acute renal failure, proximal renal tubulopathy, and Fanconi syndrome, can still occur and have been reported.[37] In HIV-infected patients starting therapy, immune reconstitution inflammatory syndrome (IRIS) can occur, where the recovering immune system mounts an inflammatory response to pre-existing opportunistic infections.[37] Postmarketing reports have included skin and subcutaneous tissue disorders such as angioedema, urticaria, and rash.[37]

C. Drug-Drug Interaction Pathways and Management

The primary mechanism for TAF's drug-drug interactions involves its role as a substrate for the P-gp and BCRP drug transporters. A summary of key interactions is provided in Table 4.

---

Table 4: Clinically Significant Drug-Drug Interactions with TAF-Based Regimens

Interacting Drug Class	Specific Drug(s)	Effect on TAF Concentration	Clinical Recommendation/Management	Source(s)
Anticonvulsants	Carbamazepine, Oxcarbazepine, Phenobarbital, Phenytoin	Decrease (Potent P-gp inducers)	Co-administration is not recommended. Consider alternative anticonvulsants.	16
Antimycobacterials	Rifampin, Rifabutin, Rifapentine	Decrease (Potent P-gp inducers)	Co-administration is not recommended due to risk of virologic failure.	16
Herbal Products	St. John's wort (Hypericum perforatum)	Decrease (P-gp inducer)	Co-administration is not recommended.	16
Protease Inhibitors	Tipranavir/ritonavir	Decrease	Co-administration is not recommended.	37
Nephrotoxic Agents	High-dose or multiple NSAIDs, Aminoglycosides, Acyclovir, Cidofovir, Ganciclovir	Increase tenofovir concentration (via reduced renal clearance)	Co-administration may increase the risk of tenofovir-related adverse reactions. Monitor renal function closely.	16

---

D. Use in Specific and Vulnerable Populations

• Renal Impairment: TAF's favorable renal profile allows its use without dose adjustment in patients with mild-to-moderate renal impairment (creatinine clearance [CrCl] ≥30 mL/min for HIV regimens, or ≥15 mL/min for Vemlidy).[21] It is generally not recommended for patients with severe renal impairment who are not on hemodialysis. For patients on chronic hemodialysis, the daily dose should be administered after completion of the dialysis session.[16]
• Hepatic Impairment: No dose adjustment is needed for mild hepatic impairment (Child-Pugh A). However, TAF is not recommended for patients with decompensated (Child-Pugh B or C) hepatic impairment.[21]
• Pregnancy and Lactation: An Antiretroviral Pregnancy Registry has been established to monitor outcomes. Women with HIV are instructed not to breastfeed due to the potential for HIV-1 transmission.[36]
• Pediatric Use: TAF's indications have been systematically expanded to younger age groups based on dedicated clinical trials, with specific weight-based criteria and, in some cases, special formulations like tablets for oral suspension.[26]

Comparative Assessment: Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate

The clinical decision to use TAF over TDF hinges on a detailed comparison of their efficacy, safety, and metabolic effects. This is not a simple matter of a newer drug being universally superior, but rather a nuanced trade-off between different long-term risk profiles. The choice requires a personalized assessment of a patient's comorbidities, risk factors, and treatment context. A summary of these comparative outcomes is presented in Table 5.

A. Antiviral Efficacy: A Nuanced View in HIV (Boosted vs. Unboosted Regimens) and HBV

• Chronic Hepatitis B: Across numerous head-to-head clinical trials, including long-term 8-year follow-up data, TAF has consistently demonstrated non-inferior antiviral efficacy to TDF in suppressing HBV DNA to undetectable levels in both HBeAg-positive and HBeAg-negative patients.[32] Some evidence suggests TAF may be associated with higher rates of ALT normalization, a marker of reduced liver inflammation.[51]
• HIV-1 Treatment: The comparative efficacy in HIV-1 is more complex and depends critically on the other drugs in the regimen.
• In unboosted regimens—which constitute the majority of modern antiretroviral therapy—meta-analyses of randomized trials show no statistically significant difference in the rates of virologic suppression between TAF- and TDF-based regimens.[3] Both formulations are highly effective.
• In boosted regimens (i.e., those containing cobicistat or ritonavir), TAF has shown a modest but statistically significant efficacy advantage over TDF.[3] This small difference is thought to be driven by the pharmacokinetic interaction between the booster and TDF, which can increase TDF-related discontinuations due to adverse events, slightly lowering the overall success rate in intention-to-treat analyses.

B. Renal Safety: Analysis of Biomarkers and Long-Term Clinical Outcomes

The primary advantage of TAF over TDF lies in its superior renal safety profile, a direct result of its lower systemic tenofovir exposure.

• Clinical Events: The difference is stark and clinically meaningful. A large pooled analysis of 26 clinical trials involving over 9,000 patients found zero cases of confirmed proximal renal tubulopathy or Fanconi syndrome in TAF-treated participants, compared to 10 cases in the TDF arms. Furthermore, discontinuations due to renal adverse events were nearly ten times less frequent with TAF (0.05%) than with TDF (0.47%).[7]
• Renal Biomarkers: TAF consistently demonstrates a more favorable impact on markers of kidney function. Compared to TDF, TAF is associated with significantly smaller decreases in estimated glomerular filtration rate (eGFR) and smaller increases in markers of proteinuria (urine albumin-to-creatinine ratio) and tubular proteinuria (retinol-binding protein and beta-2-microglobulin).[7] In studies where patients switch from TDF to TAF, these renal biomarkers often show significant improvement, indicating a degree of reversibility of TDF's effects.[56]

C. Bone Mineral Density: Impact, Reversibility, and Clinical Significance

Similar to its renal effects, TAF has a demonstrably better bone safety profile than TDF.

• Impact on BMD: In head-to-head trials, TDF is associated with statistically significant greater decreases in bone mineral density at both the hip and lumbar spine compared to TAF.[5]
• Long-Term Stability and Reversibility: Long-term 8-year data from HBV trials show that BMD remains stable in patients on continuous TAF treatment. Critically, patients who switched from TDF to TAF after 2-3 years experienced a significant improvement and partial recovery of the bone mass they had lost, with their BMD values trending back towards those of the continuous TAF group.[52] This makes TAF a preferred agent for patients with or at high risk for osteoporosis, such as older individuals and postmenopausal women.[64]

D. Metabolic Effects: Lipid Profiles and Weight Gain Considerations

The improved renal and bone safety of TAF comes with a significant metabolic trade-off.

• Lipid Profile: TDF is known to have a modest lipid-lowering effect. In contrast, initiation of or switching to TAF is consistently associated with increases in total cholesterol, LDL-cholesterol, and triglycerides compared to remaining on TDF.[48] The clinical importance of this is still under investigation. One interpretation is that TAF has a neutral effect on lipids, and the observed increases simply represent a "return to baseline" after the removal of TDF's suppressive effect.[56] Regardless of the mechanism, this finding necessitates routine lipid monitoring for patients on TAF-based regimens, and may influence the choice of therapy in patients with high baseline cardiovascular risk.
• Weight Gain: Several large cohort studies and clinical trials have associated TAF, particularly when combined with modern integrase inhibitors, with greater weight gain compared to TDF-based regimens.[67] This is an area of active research, as significant weight gain can increase the risk of metabolic syndrome and cardiovascular disease.

---

Table 5: Summary of Comparative Outcomes: Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

Clinical Endpoint	TAF Finding	TDF Finding	Key Nuance/Conclusion
HBV Virologic Suppression	High rates of durable viral suppression.	High rates of durable viral suppression.	TAF is non-inferior to TDF. Some data suggest TAF leads to better ALT normalization.
HIV Virologic Suppression	Highly effective.	Highly effective.	Non-inferior to TDF in unboosted regimens. Modest efficacy benefit over TDF only in boosted regimens.
Renal Safety (Clinical Events)	No confirmed cases of proximal tubulopathy in major trials. Very low rate (0.05%) of renal discontinuations.	Low but definite risk of proximal tubulopathy (~0.34%). Higher rate (0.47%) of renal discontinuations.	TAF has a clearly superior clinical renal safety profile.
Renal Safety (Biomarkers)	Minimal impact on eGFR; less proteinuria.	Associated with greater declines in eGFR and increases in proteinuria.	TAF is significantly less nephrotoxic based on all measured biomarkers.
Bone Mineral Density (BMD)	Minimal impact on BMD; stable over long-term use.	Associated with significant decreases in hip and spine BMD.	TAF has a clearly superior bone safety profile. Switching from TDF to TAF can lead to BMD recovery.
Lipid Profile	Associated with increases in Total Cholesterol, LDL-C, and Triglycerides.	Has a modest lipid-lowering effect.	This is the primary metabolic trade-off. TAF has a less favorable lipid profile, requiring monitoring.
Weight Gain	Associated with greater weight gain, especially with certain integrase inhibitors.	Associated with less weight gain.	A significant consideration, particularly for patients at risk of metabolic complications.

---

Evolving Evidence from Clinical Research

The clinical development program for tenofovir alafenamide continues to evolve, moving beyond foundational comparative studies to explore its utility in specific high-risk populations and to test novel therapeutic strategies. This ongoing research is refining TAF's place in clinical practice and expanding its potential applications.

A. Long-Term (8-Year) Efficacy and Safety in Chronic Hepatitis B

The final 8-year results from the pivotal Phase 3 studies (108 and 110) provide robust, long-term evidence supporting the use of TAF for chronic HBV.[48] This extensive follow-up demonstrated:

• Durable Efficacy: High rates of viral suppression (HBV DNA <29 IU/mL) were maintained through year 8, with 94-97% of patients remaining suppressed in a missing-equals-excluded analysis.[52]
• Sustained Safety: The favorable renal and bone safety profiles observed in the initial years were sustained over the long term. Patients who remained on TAF for 8 years showed stable eGFR and BMD. Those who switched from TDF to TAF experienced improvements in these parameters, which were then maintained for the remainder of the study.[48]
• High Barrier to Resistance: Critically, annual genotypic and phenotypic resistance testing revealed no development of resistance to TAF over the entire 8-year treatment period.[52] This long-term data provides profound reassurance to clinicians and patients regarding the durability and safety of lifelong TAF therapy for chronic HBV.

B. The DISCOVER Trial: TAF for HIV Pre-Exposure Prophylaxis

The DISCOVER trial (NCT02842086) was a landmark Phase 3 study that directly compared F/TAF (Descovy®) with F/TDF (Truvada®) for HIV PrEP.[68] The study enrolled over 5,000 men who have sex with men (MSM) and transgender women. The key findings were:

• Non-Inferior Efficacy: F/TAF was proven to be non-inferior to F/TDF in preventing new HIV infections. In a two-year analysis, 99.7% of participants in the Descovy arm remained HIV-negative, compared to 99.4% in the Truvada arm.[38]
• Superior Safety: Consistent with treatment studies, the F/TAF arm demonstrated statistically significant advantages in markers of renal and bone safety compared to the F/TDF arm.[70]

These results led to the FDA approval of Descovy for PrEP, providing a safer option for individuals requiring long-term prophylaxis. However, the trial's exclusion of cisgender women remains a significant data gap, and Descovy is not currently indicated for PrEP to prevent HIV acquisition via receptive vaginal sex.37

C. Investigations in Special Populations

Recent and ongoing clinical trials are focusing on populations where TAF's specific safety profile may offer a distinct advantage.

• Pediatrics: A series of studies have been conducted to establish the pharmacokinetics, safety, and efficacy of TAF-based regimens in children and adolescents, leading to the progressive expansion of approved indications to younger age groups.[27] A current Phase 1b study is evaluating the safety and pharmacokinetics of a B/F/TAF oral suspension in newborns exposed to HIV-1, a highly vulnerable population.[71]
• Organ Transplant Recipients: A completed trial (NCT02862548) specifically evaluated switching to TAF in liver transplant recipients with chronic HBV and pre-existing chronic kidney disease. The results confirmed that TAF was safe and effective in this complex population, leading to improved renal and bone parameters.[72]
• Patients with Malignancies: An ongoing trial in South Korea (NCT06221657) is comparing TAF to TDF for HBV prophylaxis in patients with hematologic malignancies undergoing immunosuppressive chemotherapy. This population is at high risk for HBV reactivation, and the study aims to confirm TAF's non-inferiority and superior safety in this setting.[73]
• New Therapeutic Paradigms: A trial in India (NCT05195450) is investigating a novel application for TAF: early treatment in non-cirrhotic, chronic HBV patients who have normal ALT levels and low viral loads. This group is not typically treated under current guidelines. The study hypothesizes that early intervention with a safe agent like TAF could prevent long-term disease progression and reduce the risk of hepatocellular carcinoma.[74] This represents a shift from treating active disease to potentially preventing its long-term consequences.

Expert Synthesis and Clinical Recommendations

A. Clinical Positioning of TAF-based Regimens

Tenofovir alafenamide has successfully established itself as the successor to TDF in many clinical contexts, fundamentally shifting the standard of care for both HIV and HBV management. Its primary clinical value is derived directly from its targeted pharmacology, which provides a superior long-term renal and bone safety profile.

Consequently, TAF-based regimens are now the preferred choice for patients with pre-existing chronic kidney disease, osteoporosis, or multiple risk factors for these conditions (e.g., older age, diabetes, concomitant nephrotoxic medications). For patients on long-term TDF therapy, particularly those who are aging, switching to a TAF-based regimen is a reasonable strategy to mitigate future renal and bone complications, with strong evidence supporting the reversibility of some TDF-associated effects.

For young, treatment-naïve patients without renal or bone comorbidities, the choice is more nuanced. While TAF still offers a theoretical long-term safety advantage, its less favorable metabolic profile (lipid elevations and weight gain) must be considered, especially in patients with or at risk for cardiovascular disease. In resource-constrained settings, the availability of low-cost, generic TDF makes it a viable and highly effective option for these lower-risk patients, a position supported by the World Health Organization.[3]

B. Key Considerations for Patient Selection and Monitoring

Effective and safe use of TAF requires careful baseline assessment and ongoing monitoring.

• Baseline Assessment:
• HBV and HIV Status: All patients must be tested for both HBV and HIV-1 infection prior to initiating any TAF-containing regimen to ensure appropriate therapy and to avoid the risks outlined in the boxed warnings.[16]
• Renal Function: A baseline assessment of serum creatinine, estimated creatinine clearance, urine glucose, and urine protein is mandatory for all patients. In those with chronic kidney disease, serum phosphorus should also be measured.[16]
• PrEP Candidacy: For individuals considering Descovy for PrEP, a negative HIV-1 test must be confirmed immediately prior to initiation.[37]
• Ongoing Monitoring:
• Renal Function: Although safer than TDF, TAF still carries a risk of nephrotoxicity. Renal function should be monitored on a clinically appropriate schedule throughout treatment.[16]
• Lipid Profile: Given the association of TAF with increases in cholesterol and triglycerides, a baseline and periodic monitoring of fasting lipid profiles is recommended.[64]
• HBV Monitoring: Patients with HBV who discontinue TAF must have their hepatic function monitored closely for several months.[21]
• HIV Screening for PrEP: Individuals using Descovy for PrEP must be screened for HIV-1 at least every three months.[37]

C. Future Directions and Unanswered Questions

Despite its widespread adoption, several important questions regarding TAF remain.

• Long-Term Cardiovascular Impact: The most significant unanswered question is the long-term clinical consequence of the lipid elevations and weight gain associated with TAF. Large, long-term observational studies are needed to determine if these metabolic changes translate into an increased risk of cardiovascular events compared to TDF.
• Efficacy in Cisgender Women for PrEP: The lack of data on the efficacy of Descovy for PrEP in cisgender women is a major gap. Clinical trials in this population are urgently needed to broaden access to safer PrEP options.
• Early HBV Intervention: The potential for TAF to alter the natural history of HBV in patients not currently eligible for treatment is an exciting frontier. The results of trials like NCT05195450 could potentially shift treatment paradigms towards earlier intervention.
• The Aging Population: As the population living with HIV and HBV continues to age, the interplay between TAF's benefits (renal/bone safety) and risks (metabolic effects) in the context of polypharmacy and multiple age-related comorbidities will require further real-world study.
• Impact of Generics: The eventual market entry of generic TAF will significantly alter cost-effectiveness calculations and may lead to broader adoption in resource-limited settings, further solidifying its role as a global standard of care.[8]

Works cited

1. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there ..., accessed July 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5892670/
2. Evidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February 2016, accessed July 26, 2025, https://www.engage.england.nhs.uk/consultation/clinical-commissioning-wave13/user_uploads/f03x08-evidence-rev.pdf
3. Meta-analysis finds no real difference in safety and effectiveness between tenofovir formulations | aidsmap, accessed July 26, 2025, https://www.aidsmap.com/news/jan-2021/meta-analysis-finds-no-real-difference-safety-and-effectiveness-between-tenofovir
4. Association of Osteoporosis-related Healthcare Costs with the Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in Chronic Hepatitis B Patients: a Population-based National Cohort Study in Korea - YAKHAK HOEJI, accessed July 26, 2025, http://www.yakhak.org/journal/view.html?uid=3341&&vmd=Full
5. Changes in bone quality after switching from a TDF to a TAF based ..., accessed July 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10083312/
6. Study Details | Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) | ClinicalTrials.gov, accessed July 26, 2025, https://clinicaltrials.gov/study/NCT03251144?term=TAF1&viewType=Table&rank=5
7. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil ..., accessed July 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6635043/
8. Tenofovir alafenamide - Wikipedia, accessed July 26, 2025, https://en.wikipedia.org/wiki/Tenofovir_alafenamide
9. Definition of tenofovir alafenamide - NCI Drug Dictionary, accessed July 26, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tenofovir-alafenamide
10. Tenofovir Alafenamide | C21H29N6O5P | CID 9574768 - PubChem, accessed July 26, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/gs-7340
11. Tenofovir alafenamide: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 26, 2025, https://go.drugbank.com/drugs/DB09299
12. GS-7340 (TAF, Tenofovir Alafenamide, CAS Number: 379270-37-8) | Cayman Chemical, accessed July 26, 2025, https://www.caymanchem.com/product/26214/gs-7340
13. Tenofovir alafenamide | HIV | Reverse Transcriptase - TargetMol, accessed July 26, 2025, https://www.targetmol.com/compound/tenofovir%20alafenamide
14. Tenofovir alafenamide ≥98% (HPLC) - Sigma-Aldrich, accessed July 26, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/sml3219
15. Tenofovir alafenamide (GS-7340) | Reverse Transcriptase Inhibitor | MedChemExpress, accessed July 26, 2025, https://www.medchemexpress.com/GS-7340.html
16. HIGHLIGHTS OF PRESCRIBING INFORMATION ... - Gilead Sciences, accessed July 26, 2025, https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdf
17. go.drugbank.com, accessed July 26, 2025, https://go.drugbank.com/salts/DBSALT002533
18. Tenofovir Alafenamide Fumarate | C46H62N12O14P2 | CID 71492247 - PubChem, accessed July 26, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Tenofovir-Alafenamide-Fumarate
19. Tenofovir Alafenamide | 379270-37-8 - ChemicalBook, accessed July 26, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB92627921.htm
20. Tenofovir Alafenamide | 99.83%(HPLC) | In Stock | Reverse Transcriptase inhibitor, accessed July 26, 2025, https://www.selleckchem.com/products/tenofovir-alafenamide-gs-7340.html
21. Clinical Resources for VEMLIDY | HCP Site, accessed July 26, 2025, https://www.vemlidyhcp.com/clinical-resources/
22. Genvoya: Uses, Dosage, Side Effects & Warnings - Drugs.com, accessed July 26, 2025, https://www.drugs.com/genvoya.html
23. US Food and Drug Administration Approves Descovy Emtricitabine Tenofovir Alafenamide Gileads Third TAF Based HIV Therapy, accessed July 26, 2025, https://www.gilead.com/news/news-details/2016/us-food-and-drug-administration-approves-descovy-emtricitabine-tenofovir-alafenamide-gileads-third-taf-based-hiv-therapy
24. 208464Orig1s000 - accessdata.fda.gov, accessed July 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208464Orig1s000AdminCorres.pdf
25. Descovy (emtricitabine and tenofovir alafenamide) FDA Approval History - Drugs.com, accessed July 26, 2025, https://www.drugs.com/history/descovy.html
26. Vemlidy (tenofovir alafenamide) FDA Approval History - Drugs.com, accessed July 26, 2025, https://www.drugs.com/history/vemlidy.html
27. FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6, accessed July 26, 2025, https://www.drugtopics.com/view/fda-expands-tenofovir-alafenamide-indication-to-treat-hbv-in-patients-as-young-as-6
28. FDA expands chronic HBV treatment to patients as young as 6 years, accessed July 26, 2025, https://www.contemporarypediatrics.com/view/fda-expands-chronic-hbv-treatment-to-patients-as-young-as-6-years
29. Drug Trials Snapshot: BIKTARVY - FDA, accessed July 26, 2025, https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-biktarvy
30. Generic version of emtricitabine/tenofovir alafenamide recommended for EU, accessed July 26, 2025, https://www.eatg.org/hiv-news/generic-version-of-emtricitabine-tenofovir-alafenamide-recommended-for-eu/
31. Descovy | European Medicines Agency (EMA), accessed July 26, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/descovy
32. Vemlidy | European Medicines Agency (EMA), accessed July 26, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/vemlidy
33. Biktarvy | European Medicines Agency (EMA), accessed July 26, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy
34. VEMLIDY® (tenofovir alafenamide) | HCP site, accessed July 26, 2025, https://www.vemlidyhcp.com/
35. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection - PubMed, accessed July 26, 2025, https://pubmed.ncbi.nlm.nih.gov/29756595/
36. DESCOVY® Healthcare Professional Website From Gilead, accessed July 26, 2025, https://www.descovy.com/hcp
37. This label may not be the latest approved by FDA. For current ..., accessed July 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208215s012lbl.pdf
38. DESCOVY for PrEP® (pre-exposure prophylaxis), accessed July 26, 2025, https://www.descovy.com/
39. Descovy Patient Drug Record | NIH - Clinical Info HIV.gov, accessed July 26, 2025, https://clinicalinfo.hiv.gov/en/drugs/emtricitabine-tenofovir-alafenamide/patient
40. Genvoya | European Medicines Agency (EMA), accessed July 26, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya
41. Genvoya Patient Drug Record | NIH - Clinical Info HIV.gov, accessed July 26, 2025, https://clinicalinfo.hiv.gov/en/drugs/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide/patient
42. Gilead Sciences 1 Patient Information GENVOYA® (jen-VOY-uh ..., accessed July 26, 2025, https://www.gilead.com/-/-/media/files/pdfs/medicines/hiv/genvoya/genvoya_patient_pi.pdf
43. Odefsey | European Medicines Agency (EMA), accessed July 26, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey
44. Odefsey Patient Drug Record | NIH - Clinical Info HIV.gov, accessed July 26, 2025, https://clinicalinfo.hiv.gov/en/drugs/emtricitabine-rilpivirine-tenofovir-alafenamide/patient
45. Odefsey (emtricitabine/rilpivirine/tenofovir AF) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed July 26, 2025, https://reference.medscape.com/drug/odefsey-emtricitabine-rilpivirine-tenofovir-af-1000079
46. 1 Patient Information ODEFSEY® (oh-DEF-see ... - Gilead Sciences, accessed July 26, 2025, https://www.gilead.com/-/media/files/pdfs/medicines/hiv/odefsey/odefsey_patient_pi.pdf
47. Vemlidy (tenofovir AF) dosing, indications, interactions, adverse effects, and more, accessed July 26, 2025, https://reference.medscape.com/drug/vemlidy-tenofovir-af-1000007
48. IDDF2024-ABS-0201 Long-term safety profile of tenofovir ... - Gut, accessed July 26, 2025, https://gut.bmj.com/content/73/Suppl_2/A255.2
49. Study Details | Study To Evaluate Emtricitabine/Tenofovir ..., accessed July 26, 2025, https://clinicaltrials.gov/study/NCT02285114
50. Study Details | Study of Bictegravir/Emtricitabine/Tenofovir ..., accessed July 26, 2025, https://clinicaltrials.gov/study/NCT02881320
51. 3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil ..., accessed July 26, 2025, https://www.xiahepublishing.com/2310-8819/JCTH-2020-00145
52. (PDF) Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials - ResearchGate, accessed July 26, 2025, https://www.researchgate.net/publication/384398014_Eight-year_efficacy_and_safety_of_tenofovir_alafenamide_for_treatment_of_chronic_hepatitis_B_virus_infection_Final_results_from_two_randomised_phase_3_trials
53. Clinical Efficacy and Safety of Long-Term Treatment of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate for Chronic Hepatitis B in Vietnam - PubMed, accessed July 26, 2025, https://pubmed.ncbi.nlm.nih.gov/38994860/
54. O31 Comparative efficacy and safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate in chronic hepatitis B: meta-analysis of randomized controlled trials | Gut, accessed July 26, 2025, https://gut.bmj.com/content/74/Suppl_1/A21
55. Tenofovir Alafenamide versus Tenofovir Disoproxil ... - Hivandmore.de, accessed July 26, 2025, https://www.hivandmore.de/kongresse/eacs2019/Pepperrell-BPD-1-1-Tenofovir-Alafenamide-versus-Tenofovir-Disoproxil-Fumarate.pdf
56. Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults - NATAP, accessed July 26, 2025, https://www.natap.org/2021/HIV/091621_02.htm
57. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials - PubMed, accessed July 26, 2025, https://pubmed.ncbi.nlm.nih.gov/31988012/
58. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results - Portal de Periódicos da CAPES, accessed July 26, 2025, https://www.periodicos.capes.gov.br/index.php/acervo/buscador.html?task=detalhes&id=W4238444439
59. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: A pooled analysis of 26 clinical trials | ID: z029pb34r | Carolina Digital Repository, accessed July 26, 2025, https://cdr.lib.unc.edu/concern/articles/z029pb34r
60. Switching from tenofovir DF to TAF improves bone and kidney safety - Aidsmap, accessed July 26, 2025, https://www.aidsmap.com/news/jul-2016/switching-tenofovir-df-taf-improves-bone-and-kidney-safety
61. P-529. Comparison of Renal Outcomes by Tenofovir Alafenamide Fumarate (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) Containing Regimens for Prevention, and Treatment of HIV and/or HBV Treatment: A Systematic Literature Review and Meta-Analysis - Oxford Academic, accessed July 26, 2025, https://academic.oup.com/ofid/article/12/Supplement_1/ofae631.728/7987433
62. Hepatitis B Treatment: Tenofovir Alafenamide Vs Tenofovir Disoproxil Fumarate, accessed July 26, 2025, https://www.contagionlive.com/view/hepatitis-b-treatment-tenofovir-alafenamide-vs-tenofovir-disoproxil-fumarate
63. TAF Is Superior to TDF in Reducing Bone, Renal Risks | Consultant360, accessed July 26, 2025, https://www.consultant360.com/exclusives/taf-superior-tdf-reducing-bone-renal-risks
64. Switching from TDF to TAF associated with improvements in bone mineral density in people over 60 | aidsmap, accessed July 26, 2025, https://www.aidsmap.com/news/nov-2019/switching-tdf-taf-associated-improvements-bone-mineral-density-people-over-60
65. Antiretroviral Associated Adverse Effects and Management Recommendations for Osteopenia and Osteoporosis | NIH, accessed July 26, 2025, https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/osteopenia-and-osteoporosis-full
66. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B | PLOS One - Research journals, accessed July 26, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0261760
67. Tenofovir alafenamide - Aidsmap, accessed July 26, 2025, https://www.aidsmap.com/about-hiv/arv-background-information/tenofovir-alafenamide
68. Tenofovir alafenamide Active Not Recruiting Phase 3 Trials for Pre-Exposure Prophylaxis of HIV-1 Infection Treatment - DrugBank, accessed July 26, 2025, https://go.drugbank.com/drugs/DB09299/clinical_trials?conditions=DBCOND0080745&phase=3&purpose=treatment&status=active_not_recruiting
69. Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/​TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (DISCOVER) - ClinicalTrials.gov, accessed July 26, 2025, https://clinicaltrials.gov/study/NCT02842086
70. Changes in Glomerular Filtration Rate After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for Human Immunodeficiency Virus Preexposure Prophylaxis | Open Forum Infectious Diseases | Oxford Academic, accessed July 26, 2025, https://academic.oup.com/ofid/article/11/2/ofad695/7503592
71. Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV, accessed July 26, 2025, https://clinicaltrials.gov/study/NCT07055451
72. Study Results | Efficacy and Safety of Tenofovir Alafenamide (TAF ..., accessed July 26, 2025, https://clinicaltrials.gov/study/NCT02862548?tab=results
73. Study Details | Clinical Trial for Non-inferiority and Safety of ..., accessed July 26, 2025, https://clinicaltrials.gov/study/NCT06221657
74. Study Details | TAF (Tenofovir Alafenamide) for Preventing ..., accessed July 26, 2025, https://clinicaltrials.gov/study/NCT05195450
75. Which Form of Tenofovir Should Be Used Worldwide: Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide? | Clinical Infectious Diseases | Oxford Academic, accessed July 26, 2025, https://academic.oup.com/cid/article-abstract/79/4/1006/7644486